International Journal of Drug Policy
Volume 21, Issue 2 , Pages 125-128, March 2010

Route transition interventions: Potential public health gains from reducing or preventing injecting

The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland

Received 30 September 2009; received in revised form 25 January 2010; accepted 25 January 2010. published online 18 February 2010.

Abstract 

Multiple factors are implicated in the diffusion of injecting drug use (IDU), including individual and demographic characteristics, drug markets, economics, social networks and political and cultural environments. However, studies show that individual transitions away from injecting are possible, and that a recent diffusion of non-injecting routes of administration (NIROA) has occurred in several countries. Injecting is more risk-laden than other routes of drug administration, yet relatively little attention has been paid to reducing or preventing injecting drug use by promoting NIROA. This commentary reviews the case for, and examples of, ‘route transition interventions’ which seek to do this. These include: prescribing oral substitutes; providing non-injecting equipment; providing safer smoking facilities; and training individuals to prevent transitions to injecting, promote NIROA, or prevent the initiation of new injectors. These initiatives have the potential—as yet largely unrealised—to offer public health gains and empower people to control and manage their drug use. Further research is needed to secure commitments at all levels to support this approach.

Keywords: Illicit Drugs, Injecting, Chasing, NIROA, Route transitions

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0955-3959(10)00012-5

doi:10.1016/j.drugpo.2010.01.011

International Journal of Drug Policy
Volume 21, Issue 2 , Pages 125-128, March 2010